Among transgender and gender-diverse adults whose gender identity is nonbinary–not exclusively male or female–and who choose low-dose hormone treatment, most prefer to continue testosterone therapy at lower-than-recommended doses after at least six months of treatment, a new study finds. The study will be presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. 

Read More